Keep Factually independent
Whether you agree or disagree with our analysis, these conversations matter for democracy. We don't take money from political groups - even a $5 donation helps us keep it that way.
Which compounding pharmacies in the U.S. offer tirzepatide 10 mg and what are their typical prices?
Executive summary
Compounded tirzepatide availability and pricing in the U.S. are contested: several lay and vendor sites list compounding pharmacies or telehealth clinics offering tirzepatide at prices typically ranging from about $200–$600 per month for higher-dose options like 7.5 mg–10 mg (examples include $599 for two vials and “$200–$400 per month” ranges) [1] [2]. However, multiple sources state that legally compounding tirzepatide in the U.S. is no longer permitted after regulators and courts ended the temporary allowance, meaning many current listings may be outdated or operate in a legal gray zone [3] [4].
1. The market picture: low-to-mid hundreds for “compounded” 7.5–10 mg offers
Several consumer-facing and telehealth pages report typical prices for compounded tirzepatide in the hundreds of dollars per month: PlushCare’s preferred pharmacy lists 7.5 mg and 10 mg options at $599 for two vials (total 4 mL) monthly [1], while price guides and aggregators commonly put reputable compounded versions in the roughly $200–$400/month band [2] [5]. Other reviews note a wide spread—some claim legitimate compounding programs around $250/month while warning of listings as low as $99 or as high as $500, and caution that very low prices may indicate risk [6] [7].
2. Who appears on vendor lists — clinics, telehealth programs, and compounding pharmacies
Articles and vendor directories name a mix of online clinics, telehealth providers, and compounding pharmacies as sources for compounded tirzepatide: examples in reporting include telehealth-linked pharmacies and larger compounding firms such as Empower Pharmacy offering tirzepatide/niacinamide injection formulations and online clinics like Shed or PlushCare partnering with state‑licensed sterile compounding pharmacies [8] [9] [1]. These pages typically emphasize compliance with USP sterile compounding standards and sometimes third-party accreditation claims [9] [8].
3. Regulatory and legal context that changes everything
Regulatory developments have significantly limited or ended lawful compounding of tirzepatide. Multiple medically reviewed and consumer‑advice sources state tirzepatide cannot be legally compounded in the U.S. now because the FDA removed it from the shortage list (October 2, 2024) and related deadlines and court rulings in 2024–2025 curtailed compounded sales—reports say compounded tirzepatide was disallowed after deadlines such as March 19, 2025, and subsequent legal rulings upheld FDA restrictions [3] [4]. That regulatory history undercuts the premise that compounding pharmacies can routinely dispense exact-copy tirzepatide today [3].
4. Branded access and alternative self-pay pricing
Eli Lilly expanded branded options and self-pay pathways: Zepbound (tirzepatide) single‑dose vials, including 7.5 mg and 10 mg, were announced at $499 through Lilly’s Self‑Pay Pharmacy Solutions, representing a manufacturer-supported, on‑label self‑pay price point that competes with the compounded price band [10] [11]. Pharmacy guides recommend pharmacists counsel patients on manufacturer savings and switching strategies rather than relying on compounded copies [10].
5. Safety, potency, and “buyer beware” warnings
Multiple sources warn compounded tirzepatide is not FDA‑approved and that quality, potency, and legality can vary widely; extremely low prices may indicate unlicensed or counterfeit supply and should raise suspicion [8] [7] [6]. Consumer guides advise choosing only licensed U.S. compounding pharmacies with transparent testing and legitimate prescriber oversight, and note insurers seldom cover branded tirzepatide for weight loss [2] [6].
6. Bottom line for readers seeking 10 mg tirzepatide
If you’re searching for a U.S. compounding pharmacy that currently offers legally compounded tirzepatide 10 mg, available sources conflict: vendor and clinic pages list providers and put typical prices in the $200–$600/month range for higher-dose packages [1] [2] [5], but regulatory and medical summaries state compounding tirzepatide is no longer legal after the FDA shortage ended and related court rulings—so many listings may be outdated or legally impermissible [3] [4]. For an on‑label route, Lilly’s self‑pay program lists single‑dose vials (7.5 mg and 10 mg) at $499 through its channel [10].
Limitations and recommended next steps: I relied only on the provided sources, which include vendor pages, aggregators, and regulatory summaries; they disagree on legality and current availability. Verify any provider’s current licensing and legal status, ask for third‑party potency testing, and consult your clinician before pursuing any compounded or self‑pay tirzepatide option [8] [7] [10].